Telix Pharmaceuticals Limited (TLX)
| Market Cap | 3.76B +19.4% |
| Revenue (ttm) | 890.79M +33.5% |
| Net Income | 33.50M +183.8% |
| EPS | 0.10 +174.8% |
| Shares Out | 339.78M |
| PE Ratio | 111.02 |
| Forward PE | 487.97 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 324,831 |
| Open | 10.92 |
| Previous Close | 10.57 |
| Day's Range | 10.66 - 10.94 |
| 52-Week Range | 6.28 - 13.11 |
| Beta | 0.56 |
| Analysts | Strong Buy |
| Price Target | 20.74 (+94.01%) |
| Earnings Date | Oct 15, 2026 |
About TLX
Telix Pharmaceuticals Limited, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic and diagnostic radiopharmaceuticals. The company operates through three segments: Precision Medicine, Therapeutics, and Manufacturing Solutions. Its lead therapeutic product candidate is TLX591, a lutetium-labeled radio antibody-drug conjugate (rADC), which is in a Phase 3 clinical trial in patients with advanced prostate cancer. The company develops TLX250, an rADC for treating advanced metastatic kidney ... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 5 analysts, the average rating for TLX stock is "Strong Buy." The 12-month stock price target is $20.74, which is an increase of 94.01% from the latest price.
News
Profound Medical, Telix Pharma Sign Co-Education Deal To Advance PSMA-Informed Prostate Care
(RTTNews) - Friday, Profound Medical Corp. (PROF) and Telix Pharmaceuticals Limited (TLX) announced a co-education agreement to educate physicians and prostate cancer centers on the complementary role...
Profound Medical enters co-education agreement with Telix Pharmaceuticals
Profound Medical (PROF) announced it is entering into a co-education agreement with Telix Pharmaceuticals (TLX). The agreement establishes a framework through which the companies intend to educate uro...
Profound Medical and Telix Pharmaceuticals Enter Co-Education Agreement to Advance PSMA-Informed Prostate Care
Collaboration will educate physicians and prostate cancer centers on the complementary roles of Telix's PSMA-PET molecular imaging technologies and Profound's MRI-guided TULSA-PRO ® Agreement provides...
First U.S. Patient Receives Telix's Newly Approved Brain Cancer Imaging Drug
(RTTNews) - Telix Pharmaceuticals Limited (TLX) announced that the first U.S. patient has been dosed with Pixclara (floretyrosine F 18 or 18F-FET), marking the commercial launch of the company's FDA-a...
Telix Pharmaceuticals’ brain cancer imaging drug applied on first U.S. patients
Telix Pharmaceuticals (TLX) announced that the first patients in the U.S. have been dosed with Pixclara – floretyrosine F 18 or 18F-FET -, its FDA-approved, amino acid positron emission tomography,…
First Patients Dosed with Telix's FDA-Approved Brain Cancer Imaging Drug Pixclara® (floretyrosine F 18)
MELBOURNE, Australia and INDIANAPOLIS, Oct. 06, 2026 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”) today announces that the first patients in the United States (U....
Ion Beam Enters Distribution Agreement For ARTMS' QIS Technology
(RTTNews) - Ion Beam Applications S.A. (IBAB.BR), a medical technology company, on Thursday announced a new agreement with ARTMS Inc., a subsidiary of Telix Pharmaceuticals Inc. (TLX) to distribute it...
IBA and Telix strengthen ties through agreement to distribute ARTMS's QIS®
IBA to offer QUANTM® Irradiation System solid-target technology to cyclotron users worldwide, scaling local production of radiometals for theranostics
Wall Street Analysts Believe Telix Pharmaceuticals Limited (TLX) Could Rally 83.42%: Here's is How to Trade
The average of price targets set by Wall Street analysts indicates a potential upside of 83.4% in Telix Pharmaceuticals Limited (TLX). While the effectiveness of this highly sought-after metric is que...
Telix Pharmaceuticals Limited Research and Development Day Transcript
Telix Pharmaceuticals Limited Research and Development Day Transcript
Telix Pharmaceuticals Transcript: R&D Day 2026
The event highlighted a robust, late-stage pipeline in prostate, kidney, and brain cancers, with multiple phase III trials and imminent product launches. Strategic partnerships, global expansion, and a theranostic platform support significant market opportunities and operational excellence.
Telix Pharmaceuticals Slides: FY 2026
Telix Pharmaceuticals has posted slides in relation to its FY 2026 quarterly earnings report, which was published on September 22, 2026.
Telix upgraded to Outperform from Sector Perform at RBC Capital
RBC Capital upgraded Telix Pharmaceuticals (TLX) to Outperform from Sector Perform with a price target of A$21, up from A$19.
RBC upgrades Telix to Outperform on ITM deal benefits
RBC Capital analyst Craig Wong-Pan upgraded Telix Pharmaceuticals (TLX) to Outperform from Sector Perform with a price target of A$21, up from A$19. The firm likes the company’s acquisition of…
Telix Beefs Up Radioisotopes Supply With $2.35 Billion Deal; Shares Crash
Telix Pharmaceuticals announced a merger with privately held ITM on Monday, leading the stock to crash despite bullish views from analysts.
Telix Pharmaceuticals Limited to Merge with ITM Isotope Technologies Munich SE Transcript
Telix Pharmaceuticals Limited to Merge with ITM Isotope Technologies Munich SE Transcript
Telix To Merge With ITM In Deal Valued At Up To $2.35 Billion
(RTTNews) - Telix Pharmaceuticals (TLX) has agreed to merge with ITM Isotope Technologies Munich SE, a company specializing in radioisotope production and radiopharmaceutical development, in a transac...
Telix Pharma To Acquire ITM In Deal Worth Up To $2.35 Bln
(RTTNews) - Telix Pharmaceuticals Ltd. (TLX,TLX.AX) announced that it signed an agreement to acquire privately held ITM Isotope Technologies Munich SE in a transaction valued at up to US$2.35 billion,...
Telix Pharmaceuticals to Acquire ITM Isotope Technologies for $1.65 Billion
Telix Pharmaceuticals to Acquire ITM Isotope Technologies for $1.65 Billion
Telix and ITM Join Forces to Create a Radiopharmaceutical Powerhouse
MELBOURNE, Australia and INDIANAPOLIS and MUNICH, Sept. 21, 2026 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”) today announces it has signed a strategic agreement ...
Telix Pharmaceuticals Transcript: M&A announcement
The merger creates a vertically integrated radiopharmaceutical leader with enhanced manufacturing, supply chain, and late-stage therapeutic assets. The $1.65B deal includes $700M in performance-based milestones and is expected to be EBITDA positive by 2027, with significant synergies and global reach.
Telix Pharmaceuticals Slides: M&A announcement
Telix Pharmaceuticals has posted slides in relation to its latest quarterly earnings report, which was published on September 20, 2026.
Telix Pharmaceuticals Press release: M&A announcement
Telix Pharmaceuticals issued a press release on September 20, 2026, disclosing material business information to investors.
Australia's Telix Pharma agrees to buy Germany's ITM Isotope for about $1.65 billion
Australia's Telix Pharmaceuticals said on Monday it has agreed to acquire Germany-based ITM Isotope Technologies Munich SE for about $1.65 billion on a cash- and debt-free basis.
Telix Pharmaceuticals Transcript: H.C. Wainwright 28th Annual Global Investment Conference
A vertically integrated radiopharma business leverages strong imaging sales to fund a late-stage pipeline in urology and neuro-oncology. Recent FDA approval of Pixclara expands the imaging portfolio, while the BiPASS and ProstACT GLOBAL 2 phase III trials advance, with key data readouts expected early next year.